Graft Versus Host Disease
Conditions
Keywords
Mesenchymal stem cell, Efficacy, Safety
Brief summary
Study Design: Treatment, Randomized, Open Label, Parallel Assignment,Safety/Efficacy Study. The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) expanded ex-vivo infusion for the treatment of patients who have developed a newly diagnosed extensive or refractory chronic graft versus host disease (chronic GVHD) to the usual therapeutic measures.
Detailed description
Chronic graft-versus-host disease (GVHD) is one of the main limitations to successful allogeneic hematopoietic stem cell transplantation (HSCT), and has a substantial impact not only on survival but also on the quality of life of otherwise cancer-free patients. Half of the patients undergoing a HLA-identical allografts who survive beyond 100 days may require long-term immunosuppressive treatment for extensive chronic GVHD, often for more than 2 years. More than one-third of patients with chronic GVHD do not respond to first-line therapy, which often involves combinations of corticosteroids and a calcineurin inhibitor. There is no standard second-line or salvage therapy for these patients and they have a poor outcome. Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic stem cells that can differentiate into various lineages and have been used to repair injured tissues. Recently, MSCs have also shown unique immunomodulatory properties ex-vivo, including inhibition of T-cell proliferation after stimulation by allo-antigens and mitogens, and prevention of the activity of cytotoxic T cells.MSCs have been used for the prophylaxis of acute GVHD and for the treatment of patients with steroid-refractory acute GVHD,but rarely have been used for extensive chronic GVHD. Development of new therapeutic agents and strategies to rescue patients with extensive chronic GVHD would provide a significant benefit in an area of unmet medical need. In this study, a single center randomized, non blinded Phase II clinical trial is proposed to study the safety and efficacy of mesenchymal stem cells (MSC) in the management of extensive chronic GVHD newly or refractory to the usual therapeutic measures. Expanded MSC will be infused at a dose of 2 million cells/kg twice a week for 2 weeks and weekly for the following two weeks (six doses totally)in patients based first-line therapy (steroid plus cyclosporin A ) or their primary immunosuppressive therapies.
Interventions
BIOLOGICALMesenchymal stem cell (MSC)
Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally). Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
DRUGPrednisone and cyclosporine or primary therapies
Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)
Sponsors
Sun Yat-sen University
Guangdong Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Informed consent obtained from patient and donor. * Any patient who has undergone allogeneic stem cell transplantation with extensive chronic GVHD. * Have not received additional agent for cGVHD within 3 months. * Expected life is more than 90 days. * Adequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease. * Adequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.
Exclusion criteria
* Invasive fungal disease. * Active cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease). * Patient is with a history of hypersensitivity to bovine products. * Relapsed malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total Response rate defined as patients with complete and partial response. | Within the first 3 months (plus or minus 7 days) after randomization |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival | Randomization until death or two years post last subject last treatment visit (or clinical cutoff) |
| Events Free Survival | Randomization until death or two years post last subject last treatment visit (or clinical cutoff) |
| The percentage of patients who can taper or discontinue the immunosuppressive agents | Randomization untill two years post the last subject last treatment visit (or clinical cutoff) |
| Serum cytokine levels and lymphocyte subsets in patients with chronic GVHD | Achieve best response within the first 3 months after randomization |
Countries
China
Outcome results
None listed